Lipocine Inc美股招股说明书(2026-02-26版)

Up to $50,000,000ofCommon Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated April 26, 2024,filed as a part of our registration statement on Form S-3 (File No. 333-275716) (the “Prior Prospectus”). This prospectus supplementshould be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the informationherein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete withoutand may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto. Under the Prior Prospectus, we registered up to an aggregate of $10,616,169 of our common stock, $0.0001 par value pershare, for offer and sale pursuant to a sales agreement, dated April 26, 2024, (the “Sales Agreement”), between us and A.G.P./AllianceGlobal Partners. From April 26, 2024 through the date of this prospectus supplement, we sold an aggregate of 1,603,431 shares of ourcommon stock, for an aggregate purchase price of $10,615,576 under the Prior Prospectus. As of the date of this prospectussupplement, we are increasing the aggregate amount of common stock that we are offering pursuant to the Sales Agreement, such thatwe are offering up to an aggregate of $50,000,000 of our common stock for sale under the Sales Agreement, including the shares ofcommon stock previously sold, or $39,384,424 from and after the date hereof. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. A.G.P. The date of this prospectus supplement is February 26, 2026.